Firmus Laboratories

Firmus Laboratories is a London-based biotechnology company dedicated to developing next-generation regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. A spin-out from University College London (UCL), the company utilizes its proprietary platform to engineer antigen-specific Tregs that restore immune tolerance. By focusing on the fundamental biology of Treg function, including the role of CTLA-4, Firmus aims to create treatments that are more precise and effective than current systemic immunosuppressants. The company is currently in the pre-clinical stage, supported by venture capital and academic partnerships. Its mission is to provide long-lasting relief for patients suffering from chronic immune-mediated conditions.